Renal Cell Carcinoma: Rationale for First-Line Combination Strategies

In this segment, Dr. Elizabeth Plimack invites both Dr. Sundhar Ramalingam and Dr. Yasser Ged to discuss the growing role of combination therapies in the first-line treatment of renal cell carcinoma. The panel reflects on the limitations of earlier single-agent approaches, including modest response rates and limited durability of benefit, which contributed to ongoing unmet clinical needs in advanced disease. Dr. Ramalingam and Dr. Ged highlight how combination strategies, particularly those incorporating immunotherapy and targeted agents, were developed to improve depth of response, extend progression-free and overall survival, and address diverse patient risk profiles. The discussion also touches on the importance of achieving early and meaningful disease control, especially for patients with more aggressive disease presentations. Overall, this segment underscores how combination regimens have been designed to overcome historical treatment gaps and better align therapeutic outcomes with the evolving expectations in renal cell carcinoma care.